November 29, 2025 - 05:43

Researchers at Örebro University have unveiled two innovative AI models capable of analyzing the brain's electrical activity to differentiate between healthy individuals and those suffering from dementia. This groundbreaking technology promises to revolutionize the diagnostic process for dementia, a condition that affects millions worldwide.
The AI models utilize advanced algorithms to interpret complex data from electroencephalogram (EEG) readings, which measure electrical activity in the brain. By identifying subtle patterns and anomalies, these models can provide rapid and reliable diagnoses, significantly reducing the time it takes for patients to receive critical care.
The implications of this research are profound, as early and accurate diagnosis of dementia can lead to better management of the disease and improved quality of life for patients and their families. As the global population ages, the need for efficient diagnostic tools becomes increasingly urgent. This development not only highlights the potential of artificial intelligence in healthcare but also paves the way for future innovations in the field.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...